Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2023-03-08 00:00:00 ET · period of report 2023-03-06 · accession 0001209191-23-017342 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-08 | 2023-03-06 | TSHA | Session R.A. II | 10% | J - Other | $0.00 | +251.3K | 9.42M | +3% | $0 |
| D | 2023-03-08 | 2023-03-06 | TSHA | Session R.A. II | 10% | D - Sale to Iss | — | -199.5K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-06 | J | A | 251,296 | $0.00 | 9,420,842 | D | — | — | (F2) Each share is represented by an RSU. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs are fully vested. (F3) In connection with the Reporting Person's separation from the Issuer, the Reporting Person forfeited 21,374 unvested shares pursuant to a restricted stock award. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-03-06 | D | D | 199,500 | — | 0 | D | $1.95 · — to 2032-11-10 | 199,500 Common Stock | (F7) This option was canceled by mutual agreement of the Issuer and the Reporting Person. The Reporting Person received the RSU Award in exchange for the cancellation of this option. (F6) Prior to the cancellation of this option, 25% of the total number of shares underlying the option were to vest and become exercisable on November 10, 2023 and the remainder were to vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |